Novel Mechanisms and Advancing Therapeutic Paradigms for Optimizing LDL-Mediated Cardioprotection


pre-program survey
We Invite You to Take a Moment and Complete This
Pre-Program Knowledge and Clinical Performance Survey.
Thank You

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in reducing LDL levels in patients with primary and familial hypercholesterolemia

Release Date

October 29, 2015

Expiration Date

October 29, 2017

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period October 29, 2015 through October 29, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 6 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.


Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

This program is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

Program Chair
President and Chief Executive Officer
National Clinical Research, Inc.
Professor Emeritus
Virginia Commonwealth University School of Medicine
Richmond, VA

Research Support: Sanofi, Regeneron, Amgen, Lilly

Professor, Epidemiology & Medicine
University of Iowa
Iowa City, Iowa

Consultant: Amgen, Eli Lilly, Merck, Pfizer, Regeneron/Sanofi
Research Grants to Institution: Amarin, Amgen, Astra-Zeneca, Esai, Glaxo-Smith Kline,
Merck, Pfizer, Regeneron/Sanofi, Takeda

Professor of Medicine
Mayo Clinic
Consultation in Cardiology
Division of Cardiology, Mayo Clinic
Rochester, Minnesota

Consultant: Sanofi, Regeneron, Astra-Zeneca,
Boehringer-Ingelheim, Pfizer

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose. Program reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Understand the unmet need for residual CV risk reduction in patients with primary hyperlipidemia and FH who are not achieving optimal LDL target goals in the setting of optimal statin-based management;
  • Determine the optimal LDL-C target goals for patients with primary hyperlipidemia and HeFH, based on a number of criteria and consensus recommendations including risk categories and/or maximally attainable LDL-C reductions;
  • Understand and act upon the clinical implications of the underlying genetic mutations, including LDLR and APOB mutations, that underpin impaired LDL receptor function or LDL removal in patients with HeFH; and how these genetic disorders have provided a portal into the understanding of novel LDL targets of possible therapeutic significance;
  • Optimally employ currently available, statin-based treatment regimens to achieve LDL-C target goals for HeFH, and be able to act upon the indications and clinical triggers for more aggressive LDL-C lowering in high risk patients;
  • Understand the types and metabolic consequences associated with the genetic underpinnings of FH and hyperlipidemia, including causes that lead to impaired LDL receptor function and impaired LDL removal; LDLR mutations, APOB mutations that impair LDLR binding and PCSK9 gain of function mutations;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2015 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.




I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC



Key Program Topics Include:

Antisense Oligonucleaotide
Apo B
Apo B-100

Dutch Lipid Clinic Network Diagnostic Criteria
Familial Hyperlipidemia


Microsomal Triglyceride Transport Protein
PCSK9 Inhibitors

Simon Broome
tendon xanthoma
UK NICE FH Guidelinesdulation